Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.

NCT05137067 is registered in ClinicalTrials.gov with Optimal Health Research as lead sponsor.

NCT NCT05137067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.
Lead sponsor
Optimal Health Research
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2021
Completion date
May 25, 2023
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lung cancer, prostate cancer